Astellas Pharma Inc 2009 AR2
The report outlines Astellas Pharma's performance and strategic direction for the fiscal year ended March 31, 2009. The company focused on its 'global category leader' business model, particularly in urology and transplantation, to drive sustainable growth despite patent expirations for key products like Prograf and Harnal. Astellas expanded its global R&D footprint, notably through the integration of Agensys, Inc. to enter the oncology field, and consolidated its drug discovery functions at the Tsukuba Research Center. Additionally, the company highlighted its commitment to corporate social responsibility across environmental, social, and compliance dimensions, including obtaining ISO14001 certification for most plants.
Company: Astellas Pharma Inc
Sector: Manufacturing
Country: Japan
Year: 2009
Type: AR2
Pages: 100
Back to company
Astellas Pharma Inc
Annual Report
The report outlines Astellas Pharma's performance and strategic direction for the fiscal year ended March 31, 2009. The company focused on its 'global category leader' business model, particularly in urology and transplantation, to drive sustainable growth despite patent expirations for key products like Prograf and Harnal. Astellas expanded its global R&D footprint, notably through the integration of Agensys, Inc. to enter the oncology field, and consolidated its drug discovery functions at the Tsukuba Research Center. Additionally, the company highlighted its commitment to corporate social responsibility across environmental, social, and compliance dimensions, including obtaining ISO14001 certification for most plants.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2009
Reporting Period
Apr 1, 2008 - Mar 31, 2009
Fiscal Year
2009
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees